NC
LRMR icon

Nexthera Capital’s Larimar Therapeutics LRMR Stock Holding History

Nexthera Capital’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-33,463
Closed -$2.99M – 51
2018
Q1 		$2.99M Buy
33,463
+19,177
+134% +$1.63M 0.49% 36
2017
Q4 		$792K Buy
+14,286
New +$644K 0.15% 37

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Nexthera Capital's LRMR Position: Q2 2018 in Review

Nexthera Capital sold out of Larimar Therapeutics (LRMR) in Q2 2018, closing a stake of 33,463 shares — an estimated $2.99M sold.

Nexthera Capital first reported a position in LRMR in Q4 2017 and held it in 2 quarters. The position peaked at $2.99M in Q1 2018. 87 funds tracked by Wall St. Rank hold LRMR as of Q2 2018.

  • Nexthera Capital reported no remaining Larimar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Nexthera Capital sold 33,463 Larimar Therapeutics shares in Q2 2018, an estimated $2.99M.
  • Nexthera Capital first reported a position in Larimar Therapeutics in Q4 2017 and held it in 2 quarters.
  • Nexthera Capital's Larimar Therapeutics position peaked at $2.99M in Q1 2018.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2018.

Based on Nexthera Capital's 13F filing for Q2 2018, filed 14 Aug 2018.